Multicenter, randomized, parallel group, phase 2 study to establish the efficacy and safety of combinations of CBP501, cisplatin, and nivolumab for greater than or equal to 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3 at screening

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Patients with pathologically confirmed stage IV exocrine pancreatic cancer who have received at least two lines of systemic therapy for metastatic disease. Up to 10 of prior lines of systemic therapy (including prior cisplatin), chemoradiotherapy, radiotherapy or investigational agents the patient has received are allowed. - Patient must not have received more than two prior lines incorporating anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade. - Radiation therapy to >30% of bone marrow prior to study entry is NOT permitted. - Evidence of peripheral neuropathy grade &#8805; 2 NOT permitted. - Active CNS mets NOT permitted.

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Wells Messersmith,  MD

Wells Messersmith, MD

Study ID

Protocol Number: 21-5119

More information available at ClinicalTrials.gov: NCT04953962

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers